TRPC1 and breast carcinoma: We demonstrate that the vulnerability of breast cancer to PEMF and DOX therapies is positively correlated with TRPC1 expression as are invasiveness and EMT (Figure 9), conferring upon them a heightened level of specificity for TRPC1-characterized cancers.